Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence

INTRODUCTION: Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is approved in the USA for relapsing MS. Following oral administration, DRF is metabolized to monomethyl fumarate, the active metabolite of dimethyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liseno, Jacob, Lager, Brittney, Miller, Catherine, Shankar, Sai L., Mendoza, Jason P., Lewin, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140165/
https://www.ncbi.nlm.nih.gov/pubmed/33846959
http://dx.doi.org/10.1007/s40120-021-00242-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140165/
https://www.ncbi.nlm.nih.gov/pubmed/33846959
http://dx.doi.org/10.1007/s40120-021-00242-7

Ejemplares similares